Neuroblastoma Clinical Trial
Official title:
Prolonged Isotretinoin Therapy in Patients With High Risk Neuroblastoma
Neuroblastoma is a cancer of the nervous system and accounts for 15% of cancer related
deaths in children. With the advancement of treatment therapies, the long term survival rate
has progressed to approximately 50%. The therapy used for treatment, however, is very toxic
and associated with serious long-term side effects. Treatment for neuroblastoma typically
includes chemotherapy, surgery, stem cell transplantation, radiation therapy, and
immunotherapy. At the end of this treatment, children with neuroblastoma commonly take the
drug isotretinoin for 6 months. Isotretinoin maintains the response to previous treatments
and helps turn the remaining cancer cells into normal nerve cells.
Most patients often respond to this treatment at first but are at a high-risk for the cancer
coming back. The majority of the children who relapse after treatment or develop recurrent
disease do so in the first two years following the completion of therapy and there are no
current treatments to cure those who relapse. This study will explore whether or not
extending the therapy with isotretinoin from 6 months to 24 months will help prevent the
cancer from coming back without causing severe side effects.
Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15%
of all pediatric cancer related deaths. The majority of patients present with high-risk
disease that is widely metastatic and aggressive. Historically, less than 30% of these
patients achieved long-term disease-free survival and the majority of relapses occurred
within the first 24 months following treatment. Survival rates have modestly improved with
the addition of high-dose chemotherapy and stem cell rescue, radiotherapy, surgery and
biologic therapy, yet 50% of patients still succumb to their disease. Current treatment of
neuroblastoma also carries significant acute toxicities and those patients that are cured
suffer significant long-term treatment-related morbidities. Therefore, children with
high-risk neuroblastoma are in need of novel therapeutic strategies that will improve cure
rates without adding to acute and long-term toxicities.
Retinoids, derivatives of vitamin A, have been repeatedly shown to arrest cell growth of
neuroblastoma cells in vitro by causing differentiation. Clinical trials in relapsed
neuroblastoma patients with bulky tumors failed to show significant responses to retinoid
therapy. Subsequently, however, a sentinel randomized clinical trial demonstrated that
isotretinoin(13-cis-retinoic acid), when given to patients with minimal residual disease
following consolidation chemotherapy, independently improved the overall survival of
patients with high-risk neuroblastoma. The treatment regimen included isotretinoin for 2
weeks followed by a 2 week rest period for 6 treatment cycles. The treatment was very well
tolerated with minimal side effects. The duration of treatment, 6 months, was arbitrarily
chosen and currently many institutions implement prolonged retinoic acid treatment in
patients with relapsed high-risk disease, yet no formal study has been done to statistically
show improved survival with prolonged biotherapy.
To improve the progression-free survival in patients with high-risk neuroblastoma this trial
will prolong therapy with isotretinoin to 24 months, the time window in which most relapses
occur. The treatment is anticipated to be well tolerated with no increase in adverse side
effects based on the benign side effect profile of patients who have received the typical 6
month treatment course. The trial will consist of a single arm of 20 high-risk neuroblastoma
patients who will receive a total of 24 cycles of isotretinoin (2 weeks on treatment
followed by 2 weeks of rest) compared to the historical and current COG study treatment of 6
cycles. Patients will be accrued over a 3-year period.
The toxicity and tolerability of a prolonged course of isotretinoin biologic therapy will be
closely monitored with a focus on neuropsychologic and bone toxicities, and isotretinoin
drug levels will be measured to determine if there is a correlation between levels and
anti-tumor efficacy or toxicities. This will provide complementary data to support future
national cooperative group trials.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00492167 -
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
|
Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03107988 -
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
|
Phase 1 | |
Recruiting |
NCT04253015 -
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
|
||
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
Recruiting |
NCT00588068 -
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
|
||
Recruiting |
NCT04301843 -
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
|
Phase 2 | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Recruiting |
NCT04040088 -
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
|
Early Phase 1 | |
Recruiting |
NCT06057948 -
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
|
Phase 2 | |
Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
Recruiting |
NCT02559778 -
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
|
Phase 2 | |
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02245997 -
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
|
N/A | |
Not yet recruiting |
NCT01156350 -
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma
|
Phase 2 | |
Active, not recruiting |
NCT01192555 -
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 |